JP2013537915A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013537915A5 JP2013537915A5 JP2013530379A JP2013530379A JP2013537915A5 JP 2013537915 A5 JP2013537915 A5 JP 2013537915A5 JP 2013530379 A JP2013530379 A JP 2013530379A JP 2013530379 A JP2013530379 A JP 2013530379A JP 2013537915 A5 JP2013537915 A5 JP 2013537915A5
- Authority
- JP
- Japan
- Prior art keywords
- salt
- oxycodone
- pharmaceutical formulation
- opioid
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims description 110
- BRUQQQPBMZOVGD-XFKAJCMBSA-N Oxycodone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(OC)C2=C5[C@@]13CCN4C BRUQQQPBMZOVGD-XFKAJCMBSA-N 0.000 claims description 96
- 229960002085 oxycodone Drugs 0.000 claims description 96
- 239000008194 pharmaceutical composition Substances 0.000 claims description 88
- 239000000203 mixture Substances 0.000 claims description 51
- 238000009472 formulation Methods 0.000 claims description 45
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 36
- 238000013270 controlled release Methods 0.000 claims description 20
- 229960005181 morphine Drugs 0.000 claims description 18
- 238000004090 dissolution Methods 0.000 claims description 17
- 230000036470 plasma concentration Effects 0.000 claims description 16
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims description 12
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims description 12
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 8
- IJVCSMSMFSCRME-KBQPJGBKSA-N Dihydromorphine Chemical compound O([C@H]1[C@H](CC[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O IJVCSMSMFSCRME-KBQPJGBKSA-N 0.000 claims description 6
- UQCNKQCJZOAFTQ-ISWURRPUSA-N Oxymorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O UQCNKQCJZOAFTQ-ISWURRPUSA-N 0.000 claims description 6
- 229960004126 codeine Drugs 0.000 claims description 6
- RBOXVHNMENFORY-DNJOTXNNSA-N dihydrocodeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC RBOXVHNMENFORY-DNJOTXNNSA-N 0.000 claims description 6
- 229960000920 dihydrocodeine Drugs 0.000 claims description 6
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims description 6
- 229960000240 hydrocodone Drugs 0.000 claims description 6
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims description 6
- 229960001410 hydromorphone Drugs 0.000 claims description 6
- 229960005118 oxymorphone Drugs 0.000 claims description 6
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims description 6
- 239000002632 kappa opiate receptor agonist Substances 0.000 claims description 4
- 239000002756 mu opiate receptor agonist Substances 0.000 claims description 4
- 229940005483 opioid analgesics Drugs 0.000 claims description 3
- 229940121954 Opioid receptor agonist Drugs 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000003402 opiate agonist Substances 0.000 claims description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 2
- 238000000034 method Methods 0.000 description 5
- 241000282412 Homo Species 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38622710P | 2010-09-24 | 2010-09-24 | |
| US61/386,227 | 2010-09-24 | ||
| US13/024,319 | 2011-02-09 | ||
| US13/024,319 US20110195989A1 (en) | 2010-02-09 | 2011-02-09 | Controlled Release Formulations of Opioids |
| PCT/US2011/053132 WO2012040651A2 (en) | 2010-09-24 | 2011-09-23 | Controlled release formulations of opioids |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013537915A JP2013537915A (ja) | 2013-10-07 |
| JP2013537915A5 true JP2013537915A5 (enExample) | 2014-11-06 |
Family
ID=44741728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013530379A Pending JP2013537915A (ja) | 2010-09-24 | 2011-09-23 | オピオイドの制御放出製剤 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP2618820A2 (enExample) |
| JP (1) | JP2013537915A (enExample) |
| CN (1) | CN103476403A (enExample) |
| AU (1) | AU2011305161A1 (enExample) |
| CA (1) | CA2812570A1 (enExample) |
| WO (1) | WO2012040651A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040253310A1 (en) | 2001-09-21 | 2004-12-16 | Gina Fischer | Morphine polymer release system |
| WO2003024429A1 (en) | 2001-09-21 | 2003-03-27 | Egalet A/S | Polymer release system |
| US8877241B2 (en) | 2003-03-26 | 2014-11-04 | Egalet Ltd. | Morphine controlled release system |
| US8821928B2 (en) | 2007-06-04 | 2014-09-02 | Egalet Ltd. | Controlled release pharmaceutical compositions for prolonged effect |
| AU2010265213B2 (en) | 2009-06-24 | 2012-08-23 | Egalet Ltd. | Controlled release formulations |
| AU2013204592A1 (en) * | 2012-04-09 | 2013-10-24 | QRxPharma Ltd. | Controlled release formulations of opioids |
| JP2015521988A (ja) | 2012-07-06 | 2015-08-03 | イガレット・リミテッド | 制御放出用乱用防止性医薬組成物 |
| DK3169315T3 (da) * | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
| US12161754B2 (en) | 2017-12-20 | 2024-12-10 | Purdue Pharma L.P. | Abuse deterrent morphine sulfate dosage forms |
| CN114515282B (zh) * | 2020-11-19 | 2023-09-08 | 山东大学 | Sorbic acid在制备抗冠状病毒感染药物中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5965161A (en) * | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
| US20060240105A1 (en) * | 1998-11-02 | 2006-10-26 | Elan Corporation, Plc | Multiparticulate modified release composition |
| US6419960B1 (en) * | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| UA81224C2 (uk) * | 2001-05-02 | 2007-12-25 | Euro Celtic S A | Дозована форма оксикодону та її застосування |
| US20030092724A1 (en) * | 2001-09-18 | 2003-05-15 | Huaihung Kao | Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic |
| WO2003039561A1 (en) * | 2001-11-02 | 2003-05-15 | Elan Corporation, Plc | Pharmaceutical composition |
| US8906413B2 (en) * | 2003-05-12 | 2014-12-09 | Supernus Pharmaceuticals, Inc. | Drug formulations having reduced abuse potential |
| US20090233841A1 (en) | 2005-01-05 | 2009-09-17 | Regents Of The University Of Minnesota | Analgesic conjugates |
| EP1863456A1 (en) * | 2005-03-28 | 2007-12-12 | Orexo AB | New pharmaceutical compositions useful in the treatment of pain |
| US20090082466A1 (en) | 2006-01-27 | 2009-03-26 | Najib Babul | Abuse Resistant and Extended Release Formulations and Method of Use Thereof |
| JP2010509227A (ja) * | 2006-11-07 | 2010-03-25 | ネクター セラピューティックス エイエル，コーポレイション | オピオイド作動薬およびオピオイド拮抗薬の用量形態および同時投与 |
| AU2009203070A1 (en) * | 2008-05-20 | 2009-12-10 | Qrxpharma Limited | Dual opioid pain therapy |
| US20110195989A1 (en) * | 2010-02-09 | 2011-08-11 | Rudnic Edward M | Controlled Release Formulations of Opioids |
-
2011
- 2011-09-23 WO PCT/US2011/053132 patent/WO2012040651A2/en not_active Ceased
- 2011-09-23 AU AU2011305161A patent/AU2011305161A1/en not_active Abandoned
- 2011-09-23 JP JP2013530379A patent/JP2013537915A/ja active Pending
- 2011-09-23 CN CN2011800562785A patent/CN103476403A/zh active Pending
- 2011-09-23 EP EP11764653.9A patent/EP2618820A2/en not_active Withdrawn
- 2011-09-23 CA CA2812570A patent/CA2812570A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011137020A5 (enExample) | ||
| JP2018109059A (ja) | オピオイドアゴニストおよび隔離されているアンタゴニストを含む医薬組成物 | |
| KR102082529B1 (ko) | 오피오이드-유도 유해 약역학 반응을 치료하기 위한 시스템 및 방법 | |
| JP2007506766A5 (enExample) | ||
| JP2014504630A5 (enExample) | ||
| RU2013117274A (ru) | Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов | |
| JP2017513809A5 (enExample) | ||
| EP2793868A1 (en) | Multiple unit pellet tablet formulation comprising an opioid | |
| RU2011104146A (ru) | Фармацевтическая композиция, содержащая опиоидный антагонист, для лечения задержки мочи | |
| JP2013537915A (ja) | オピオイドの制御放出製剤 | |
| JP2012502103A5 (enExample) | ||
| Yu et al. | Thienorphine is a potent long-acting partial opioid agonist: a comparative study with buprenorphine | |
| CA2569742A1 (en) | Opioids for the treatment of the restless leg syndrome | |
| US8933092B2 (en) | Methods and compositions comprising sequential administration opioid receptor agonists | |
| JP2004529959A (ja) | 鎮痛剤組成物と手法 | |
| JP2017526719A5 (enExample) | ||
| US20160074387A1 (en) | Systems and Methods for Attenuating Opioid-Induced Euphoria | |
| US20170035765A1 (en) | Method of treating pulmonary arterial hypertension | |
| JP2020073583A (ja) | ミューオピオイド受容体アンタゴニストとオピオイド剤との組み合わせ剤形 | |
| US10022377B2 (en) | Method of treating hypertension | |
| WO2015089614A1 (en) | Stable oral pharmaceutical composition | |
| US20040116352A1 (en) | Active substance combination containing a compound with an opioid effect and at least one further compound of formula 1 | |
| TW201216965A (en) | improving the characteristics of Nalbuphine in low oral bioavailability, and developing thenew oral dosage form and new dosage | |
| HK1191570A (en) | Pharmaceutical composition comprising opioid agonist and sequestered antagonist | |
| JP2013537232A5 (enExample) |